Unlocking the Power of Immune Engineering
Pioneering next-generation immunotherapy to transform invisible cancer cells into visible targets
Our Mission
At Lurex Bio Inc., we are reimagining immunotherapy through precision design, elegant simplicity, and translational potential.
Our mission is to reactivate the body's natural defenses against cold tumors that escape immune detection. By fusing synthetic immune signals directly onto tumor cell membranes, we transform invisible cancer cells into visible targets recognized by the body's own T-cells and natural killer cells.
Through our proprietary technology platforms—NeoTag™, Atraxis™, Atraxis-X™, and DeltaGate Logic™—we work to overcome tumor immune evasion and bring new hope to patients.
Precision
Targeted immune engineering
Simplicity
Elegant design solutions
Translation
Science to patient impact
Proprietary Technology Platforms
Four integrated systems working in concert to reactivate immune responses against cold tumors
Lurex Bio's technology stack represents a unified approach to immune engineering. Each platform—NeoTag™, Atraxis™, Atraxis-X™, and DeltaGate Logic™—addresses a distinct layer of immune activation, from tumor tagging and membrane fusion to adaptive signal control. Together, these platforms form a modular architecture that transforms immune-silent tumors into visible, targetable cells while maintaining precision, safety, and scalability across multiple disease categories.
Precision immune-tagging platform that identifies and flags immune-silent tumor cells for recognition
Innovative immune-engineering platform that unites synthetic immune cues with tumor biology to restore recognition.
Advancing the Atraxis platform through adaptive technology that delivers precision control and timing in therapeutic deployment.
Adaptive bio-decision logic system delivering precision and safety across diverse disease applications while protecting healthy tissue
How Our Platforms Work
A unified system of next-generation technologies that redefines how the immune system sees and responds to disease — with broad potential across oncology, autoimmune, and other immune-driven conditions. The adaptive delivery architecture also offers opportunities for collaboration and licensing, enabling precision delivery of therapeutic agents across the biotech and pharmaceutical landscape.
Synthetic Immune Signals
NeoTag™ is designed to apply engineered immune markers that enable immune-silent tumor cells to become visible to the body's defenses.
Precision Delivery
The Atraxis™, Atraxis-X™, and DeltaGate Logic™ platforms are designed to coordinate precision-timed therapeutic engagement, enabling controlled activation within cold tumor environments while safeguarding healthy tissue.
Immune Activation
DeltaGate Logic™ is designed to orchestrate precision immune engagement, restoring targeted immune awareness against tumors that evade detection.
Benefits of Our Approach
Redefining immune precision through clean, controllable, and compatible design
Clean by Design
Non-genetic, non-viral immune engineering
Durable Yet Reversible
Lasting engagement with controlled modulation
Broad Compatibility
Integrates with existing therapeutic modalities
Safety Through Precision
Context-specific activation for minimal off-target effects
Our Solutions
Pioneering immune-engineering platforms designed to detect, engage, and resolve disease through next-generation innovation.
NeoTag™
Synthetic immune signals fused directly onto tumor cell membranes
Atraxis™ & Atraxis-X™
Advanced therapeutic delivery systems for precision targeting
DeltaGate Logic™
Intelligent control systems for immune response optimization